Navigation Links
Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
Date:3/2/2011

SAN DIEGO, March 2, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Cowen & Co. 31st Annual Health Care Conference in Boston.

The live presentation takes place on Wednesday, March 9, 2011 at 10:15 a.m. Eastern Time / 7:15 a.m. Pacific Time.  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at (858) 617-7600.  Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
2. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
3. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
4. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
5. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
7. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
8. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
9. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
10. Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
11. Neurocrine Biosciences Amends Corporate Headquarters Lease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... June 28, 2017 Michael Zasloff , ... University School of Medicine, and Founder, Chairman and CEO ... study that has helped clarify the function of alpha-Synuclein ... other neurodegenerative diseases. Denise Barbut , MD, FRCP, ... was senior co-author of the study. Published ...
(Date:6/28/2017)... ... June 28, 2017 , ... ... three research projects accepted for presentation at the 33rd Annual Meeting of the ... – including some of the world’s top thought leaders in reproductive medicine – ...
(Date:6/28/2017)... and London, June 28, 2017 (PRWEB) , ... ... ... The latest release of Siemens’ STAR-CCM+® software for multiphysics computational fluid ... enable automated product design exploration and optimization. STAR-CCM+ version 12.04 introduces Design ...
(Date:6/28/2017)... NC (PRWEB) , ... June 28, 2017 , ... Studies ... might lead to an effective treatment for Parkinson’s disease. But what has not been ... should take place to gain the best results. , A new study coming out ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and Markets ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 8.8% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):